ResearchMoz

Pharmaceuticals and Healthcare Market Research Reports & Industry Analysis

The Pharmaceutical Industry is a key segment for global economical growth. While the industry is dominated ...

Pharmaceuticals and Healthcare

Sub Category

Browse reports in Pharmaceuticals and Healthcare

Displaying 251 to 280 (of 5433 records)
Pages: « Prev  4 5 6 7 8 9 10 11 12 13   Next »
Impetigo Global Clinical Trials Review, H1, 2013
Mar 2013   |   By - GlobalData
Impetigo Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, Impetigo Global Clinical Trials Review, H1, 2013" provides data on the Impetigo clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Impetigo. It includes an overview of the trial numbers and their recruitment status as per the site of trial...
$2500
Cholestasis Global Clinical Trials Review, H1, 2013
Mar 2013   |   By - GlobalData
Cholestasis Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, Cholestasis Global Clinical Trials Review, H1, 2013" provides data on the Cholestasis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cholestasis. It includes an overview of the trial numbers and their recruitment status as per the...
$2500
Cholangitis Global Clinical Trials Review, H1, 2013
Mar 2013   |   By - GlobalData
Cholangitis Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, Cholangitis Global Clinical Trials Review, H1, 2013" provides data on the Cholangitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cholangitis. It includes an overview of the trial numbers and their recruitment status as per the...
$2500
Vitiligo Global Clinical Trials Review, H1, 2013
Mar 2013   |   By - GlobalData
Vitiligo Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, Vitiligo Global Clinical Trials Review, H1, 2013" provides data on the Vitiligo clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Vitiligo. It includes an overview of the trial numbers and their recruitment status as per the site of trial...
$2500
Cholecystitis Global Clinical Trials Review, H1, 2013
Mar 2013   |   By - GlobalData
Cholecystitis Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, Cholecystitis Global Clinical Trials Review, H1, 2013" provides data on the Cholecystitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cholecystitis. It includes an overview of the trial numbers and their recruitment status as...
$2500
Rosacea Global Clinical Trials Review, H1, 2013
Mar 2013   |   By - GlobalData
Rosacea Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, Rosacea Global Clinical Trials Review, H1, 2013" provides data on the Rosacea clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Rosacea. It includes an overview of the trial numbers and their recruitment status as per the site of trial...
$2500
Vasculitis Global Clinical Trials Review, H1, 2013
Mar 2013   |   By - GlobalData
Vasculitis Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, Vasculitis Global Clinical Trials Review, H1, 2013" provides data on the Vasculitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Vasculitis. It includes an overview of the trial numbers and their recruitment status as per the site...
$2500
Retinal Vein Occlusion Global Clinical Trials Review, H1, 2013
Mar 2013   |   By - GlobalData
Retinal Vein Occlusion Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, Retinal Vein Occlusion Global Clinical Trials Review, H1, 2013" provides data on the Retinal Vein Occlusion clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Retinal Vein Occlusion. It includes an overview of the trial...
$2500
EpiCast Report: Hepatitis C Virus - Epidemiology Forecast to 2022
Mar 2013   |   By - GlobalData
EpiCast Report: Hepatitis C Virus - Epidemiology Forecast to 2022 Summary Hepatitis C is a largely asymptomatic liver disease caused by the hepatitis C virus (HCV). HCV is an escalating public health problem and burdens an estimated 3% of the worlds population (Trinks et al., 2012). Unlike other acute viral infections that have a rapid onset, HCV infections often persist for decades (CDC,...
$3995
EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2022
Mar 2013   |   By - GlobalData
EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) Epidemiology Forecast to 2022 Summary Lung cancer is a disease of uncontrolled cell growth in the lung tissues. It is one of the most commonly occurring cancers in the world, representing almost 13% of all cancers (Ferlay et al., 2010). NSCLC is the most common type of lung cancer, comprising about 85% of all lung...
$3995
PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022
Mar 2013   |   By - GlobalData
PharmaPoint: Multiple Sclerosis US Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis US Drug Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and...
$4995
PharmaPoint: Multiple Sclerosis - UK Drug Forecast and Market Analysis to 2022
Mar 2013   |   By - GlobalData
PharmaPoint: Multiple Sclerosis UK Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis UK Drug Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and...
$4995
PharmaPoint: Multiple Sclerosis - Spain Drug Forecast and Market Analysis to 2022
Mar 2013   |   By - GlobalData
PharmaPoint: Multiple Sclerosis Spain Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis Spain Drug Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal...
$4995
PharmaPoint: Multiple Sclerosis - Japan Drug Forecast and Market Analysis to 2022
Mar 2013   |   By - GlobalData
PharmaPoint: Multiple Sclerosis Japan Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis Japan Drug Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal...
$4995
PharmaPoint: Multiple Sclerosis - Italy Drug Forecast and Market Analysis to 2022
Mar 2013   |   By - GlobalData
PharmaPoint: Multiple Sclerosis Italy Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis Italy Drug Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection...
$4995
PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022
Mar 2013   |   By - GlobalData
PharmaPoint: Multiple Sclerosis India Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis India Drug Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection...
$4995
Gilenya (Multiple Sclerosis) - Forecast and Market Analysis to 2022
Mar 2013   |   By - GlobalData
Gilenya (Multiple Sclerosis) Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Gilenya (Multiple Sclerosis) Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and...
$6995
Rebif (Multiple Sclerosis) - Forecast and Market Analysis to 2022
Mar 2013   |   By - GlobalData
Rebif (Multiple Sclerosis) Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Rebif (Multiple Sclerosis) Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and...
$6995
Tysabri (Multiple Sclerosis) - Forecast and Market Analysis to 2022
Mar 2013   |   By - GlobalData
Tysabri (Multiple Sclerosis) Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Tysabri (Multiple Sclerosis) Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and...
$6995
Betaseron/Betaferon (Multiple Sclerosis) - Forecast and Market Analysis to 2022
Mar 2013   |   By - GlobalData
Betaseron/Betaferon (Multiple Sclerosis) Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Betaseron/Betaferon (Multiple Sclerosis) Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination,...
$6995
Avonex (Multiple Sclerosis) - Forecast and Market Analysis to 2022
Mar 2013   |   By - GlobalData
Avonex (Multiple Sclerosis) Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Avonex (Multiple Sclerosis) Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and...
$6995
Copaxone (Multiple Sclerosis) - Forecast and Market Analysis to 2022
Mar 2013   |   By - GlobalData
Copaxone (Multiple Sclerosis) Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Copaxone (Multiple Sclerosis) Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and...
$6995
PharmaPoint: Multiple Sclerosis - Germany Drug Forecast and Market Analysis to 2022
Mar 2013   |   By - GlobalData
PharmaPoint: Multiple Sclerosis Germany Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis Germany Drug Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal...
$4995
PharmaPoint: Multiple Sclerosis - France Drug Forecast and Market Analysis to 2022
Mar 2013   |   By - GlobalData
PharmaPoint: Multiple Sclerosis France Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis France Drug Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal...
$4995
PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022
Mar 2013   |   By - GlobalData
PharmaPoint: Multiple Sclerosis China Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis China Drug Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal...
$4995
PharmaPoint: Multiple Sclerosis - Canada Drug Forecast and Market Analysis to 2022
Mar 2013   |   By - GlobalData
PharmaPoint: Multiple Sclerosis Canada Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis Canada Drug Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal...
$4995
PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022
Mar 2013   |   By - GlobalData
PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, "PharmaPoint: Multiple Sclerosis - UK Drug Forecast and Market Analysis to 2022". Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal...
$4995
Aubagio (Multiple Sclerosis) - Forecast and Market Analysis to 2022
Mar 2013   |   By - GlobalData
Aubagio (Multiple Sclerosis) Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Aubagio (Multiple Sclerosis) Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and...
$3495
BG-12 (Multiple Sclerosis) - Forecast and Market Analysis to 2022
Mar 2013   |   By - GlobalData
BG-12 (Multiple Sclerosis) Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “BG-12 (Multiple Sclerosis) Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and...
$3495
Lemtrada (Multiple Sclerosis) - Forecast and Market Analysis to 2022
Mar 2013   |   By - GlobalData
Lemtrada (Multiple Sclerosis) Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Lemtrada (Multiple Sclerosis) Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and...
$3495
 
Displaying 251 to 280 (of 5433 records)
Pages: « Prev  4 5 6 7 8 9 10 11 12 13   Next »